Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Two Parallel Groups, International Multicenter Trial to Evaluate the Effect of Plerixafor in Acute Respiratory Failure Related to COVID-19.

NCT05411575 is registered in ClinicalTrials.gov with 4Living Biotech as lead sponsor.

NCT NCT05411575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Two Parallel Groups, International Multicenter Trial to Evaluate the Effect of Plerixafor in Acute Respiratory Failure Related to COVID-19.
Lead sponsor
4Living Biotech
Phase
Phase 2
Overall status
Withdrawn
Start date
July 19, 2022
Completion date
October 31, 2022
Enrollment
0 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, covid-19 acute respiratory distress syndrome